Herpes simplex - Herpes Rọrun
☆ AI Dermatology — Free Service
Ninu awọn abajade 2022 Stiftung Warentest lati Jẹmánì, itẹlọrun alabara pẹlu ModelDerm jẹ kekere diẹ ju pẹlu awọn ijumọsọrọ telemedicine isanwo.
Ninu awọn abajade 2022 Stiftung Warentest lati Jẹmánì, itẹlọrun alabara pẹlu ModelDerm jẹ kekere diẹ ju pẹlu awọn ijumọsọrọ telemedicine isanwo.
Herpes simplex lori agbegbe yii.
Herpes Rọrun (Herpes simplex) – Ikọlu Herpes simplex lórí àwọn ìka ọwọ́ jẹ́ wọ́pọ̀ jù lọ ní àwọn ọmọde ju àwọn agbalagba lọ.
relevance score : -100.0%
ReferencesIkolu HSV-1 nlọsiwaju nipasẹ ikolu akọkọ ti awọn sẹẹli epithelial, ti o tẹle pẹlu lairi, ni pato ninu awọn neuron, ati atunṣe. HSV-1 ti o wọpọ nfa ibẹrẹ ati awọn eruptions vesicular loorekoore, paapaa lori ẹnu ati mucosa abe. Awọn ifihan rẹ wa lati Herpes orolabial si ọpọlọpọ awọn ipo bii herpetic folliculitis, awọn akoran awọ ara, ilowosi oju, ati awọn ọran ti o nira bii Herpes encephalitis. Itọju ọlọjẹ n ṣe iranlọwọ lati ṣakoso ikolu HSV.
Herpes simplex virus type 1 (HSV-1) is a member of the Alphaherpesviridae subfamily. Its structure is composed of linear dsDNA, an icosahedral capsid that is 100 to 110 nm in diameter, with a spikey envelope. In general, the pathogenesis of HSV-1 infection follows a cycle of primary infection of epithelial cells, latency primarily in neurons, and reactivation. HSV-1 is responsible for establishing primary and recurrent vesicular eruptions, primarily in the orolabial and genital mucosa. HSV-1 infection has a wide variety of presentations, including orolabial herpes, herpetic sycosis (HSV folliculitis), herpes gladiatorum, herpetic whitlow, ocular HSV infection, herpes encephalitis, Kaposi varicelliform eruption (eczema herpeticum), and severe or chronic HSV infection. Antiviral therapy limits the course of HSV infection.
Herpes simplex virus type 1 (HSV-1) is a member of the Alphaherpesviridae subfamily. Its structure is composed of linear dsDNA, an icosahedral capsid that is 100 to 110 nm in diameter, with a spikey envelope. In general, the pathogenesis of HSV-1 infection follows a cycle of primary infection of epithelial cells, latency primarily in neurons, and reactivation. HSV-1 is responsible for establishing primary and recurrent vesicular eruptions, primarily in the orolabial and genital mucosa. HSV-1 infection has a wide variety of presentations, including orolabial herpes, herpetic sycosis (HSV folliculitis), herpes gladiatorum, herpetic whitlow, ocular HSV infection, herpes encephalitis, Kaposi varicelliform eruption (eczema herpeticum), and severe or chronic HSV infection. Antiviral therapy limits the course of HSV infection.
Herpes simplex virus type 2 (HSV-2) jẹ akoran tí ń tan kaakiri, tí ó kan nípa 22 % ti àwọn àgbàlagbà tó wà láàrin ọdún 12 àti ju bẹ́ẹ̀ lọ, pẹ̀lú àkúnya tó tó 45 milionu ní Amẹ́ríkà. Bí HSV-1 ṣe máa ń fa àrùn ẹnu, ó tún lè yọrí sí àrùn àbẹ̀. Ṣùgbọ́n nígbà tí aláìsàn bá ní ọ̀gbẹ́ abẹ ara, HSV-2 sábà máa ń jẹ́ ìbànújẹ́ àkọ́kọ́. Àwọn ààmì àìlera HSV-2 máa ń hàn ní àìdá, bíi irẹ̀jẹ̀ àbò àti irora, èyí tí ó lè fa ìdádúró ní ìwádìí àrùn àti ìtọ́jú. Ìdádúró yìí lè yọrí sí ìtànkálẹ̀ sí àwọn ènìyàn tí kò ní àrùn.
Herpes simplex virus type 2 (HSV-2) continues to be a common infection, affecting approximately 22% of adults ages 12 and older, representing 45 million adults in the United States alone. While HSV-1 often affects the perioral region and can be known to cause genital lesions, HSV-2 is more commonly the consideration when patients present with genital lesions. Despite this, most outbreaks of the infection will present with nonspecific symptoms such as genital itching, irritation, and excoriations, which may cause diagnosis and treatment to be delayed. As a result, further exposure to uninfected individuals may occur.
Herpes simplex virus type 2 (HSV-2) continues to be a common infection, affecting approximately 22% of adults ages 12 and older, representing 45 million adults in the United States alone. While HSV-1 often affects the perioral region and can be known to cause genital lesions, HSV-2 is more commonly the consideration when patients present with genital lesions. Despite this, most outbreaks of the infection will present with nonspecific symptoms such as genital itching, irritation, and excoriations, which may cause diagnosis and treatment to be delayed. As a result, further exposure to uninfected individuals may occur.
Herpes simplex virus (HSV) nigbagbogbo nfa awọn akoran bii Herpes abe ati ọgbẹ tutu ni awọn ọdọ ati awọn agbalagba. Nigbati HSV ba nfa ọmọ ikoko laarin ọsẹ 4‑6 akọkọ ti igbesi aye, o le ja si aisan to lagbara pẹlu awọn abajade to ṣe pataki. Ní kíákíá, ṣe ìwádìí aisan HSV ọmọ tuntun jẹ́ pàtàkì láti dènà kí arun náà má bà jù, kí a lè yago fún àwọn ọ̀ràn iṣan (páàpáà ikú).
Herpes simplex virus (HSV), a member of the Herpesviridae family, is a well-known cause of infections including genital herpes and herpes labialis in the adolescent and adult population. Transmission of HSV infection to an infant during the first 4-6 weeks of life can lead to devastating disease with the potential for poor outcomes. Early diagnosis is imperative when evaluating neonatal HSV infection in order to prevent further disease progression, neurological complications, and even death.
Herpes simplex virus (HSV), a member of the Herpesviridae family, is a well-known cause of infections including genital herpes and herpes labialis in the adolescent and adult population. Transmission of HSV infection to an infant during the first 4-6 weeks of life can lead to devastating disease with the potential for poor outcomes. Early diagnosis is imperative when evaluating neonatal HSV infection in order to prevent further disease progression, neurological complications, and even death.
Herpes simplex ikolu jẹ arun ti o wọpọ ati pe o le gba lati ọdọ awọn aboyun si awọn ọmọ wọn. Kokoro yii le fa awọn iṣoro ilera to ṣe pataki tabi paapaa iku ninu awọn ọmọ tuntun. Lakoko ti o le jẹ toje lakoko oyun funrararẹ, o maa n ṣẹlẹ lakoko ibimọ. Ewu ti o ga julọ ti iya ba ni akoran ni awọn ipele nigbamii ti oyun. Sibẹsibẹ, ewu yii le dinku nipasẹ lilo awọn oogun antiviral tabi jijẹ jade fun apakan C ni awọn ipo kan.
Infection with herpes simplex is one of the most common sexually transmitted infections. Because the infection is common in women of reproductive age it can be contracted and transmitted to the fetus during pregnancy and the newborn. Herpes simplex virus is an important cause of neonatal infection, which can lead to death or long-term disabilities. Rarely in the uterus, it occurs frequently during the transmission delivery. The greatest risk of transmission to the fetus and the newborn occurs in case of an initial maternal infection contracted in the second half of pregnancy. The risk of transmission of maternal-fetal-neonatal herpes simplex can be decreased by performing a treatment with antiviral drugs or resorting to a caesarean section in some specific cases.
Infection with herpes simplex is one of the most common sexually transmitted infections. Because the infection is common in women of reproductive age it can be contracted and transmitted to the fetus during pregnancy and the newborn. Herpes simplex virus is an important cause of neonatal infection, which can lead to death or long-term disabilities. Rarely in the uterus, it occurs frequently during the transmission delivery. The greatest risk of transmission to the fetus and the newborn occurs in case of an initial maternal infection contracted in the second half of pregnancy. The risk of transmission of maternal-fetal-neonatal herpes simplex can be decreased by performing a treatment with antiviral drugs or resorting to a caesarean section in some specific cases.
Herpes simplex virus (HSV) orisi 1 ati 2 nfa akoran pupọ laarin awọn eniyan kakiri agbaye. Nigbagbogbo, ọlọjẹ naa dakẹ ninu awọn sẹẹli nàfú lẹ́yìn tí ó bá wọ̀ǹ ní àwọ̀ ara, ṣùgbọ́n ó lè tún ṣíṣe lẹ́ẹ̀kansi, tí yóò sì fa àwọn ọ̀gbẹ́ tutu. Nígbà míì, ó lè yọrí sí àwọn iṣoro tó lagbara bíi àkóràn ojú, ìgbóná ọpọlọ, tàbí àwọn ipo tó lèwu fún àwọn ọmọ ikoko àti àwọn ènìyàn tí ó ní eto ajẹsara aláìlera. Bí ó tilẹ̀ jẹ́ pé àwọn òògùn tó wà lónìí ń ràn wá lọ́wọ́ láti ṣàkóso àkóràn, eewu ìdáwọ̀lẹ̀ òògùn àti àwọn àkúnya ẹgbẹ́ jẹ́ àníyàn kan. A nílò àwọn òògùn tuntun láti dojú kọ́ ọlọjẹ náà dáadáa.
Infection with herpes simplex virus (HSV) types 1 and 2 is ubiquitous in the human population. Most commonly, virus replication is limited to the epithelia and establishes latency in enervating sensory neurons, reactivating periodically to produce localized recurrent lesions. However, these viruses can also cause severe disease such as recurrent keratitis leading potentially to blindness, as well as encephalitis, and systemic disease in neonates and immunocompromised patients. Although antiviral therapy has allowed continual and substantial improvement in the management of both primary and recurrent infections, resistance to currently available drugs and long-term toxicity pose a current and future threat that should be addressed through the development of new antiviral compounds directed against new targets.
Infection with herpes simplex virus (HSV) types 1 and 2 is ubiquitous in the human population. Most commonly, virus replication is limited to the epithelia and establishes latency in enervating sensory neurons, reactivating periodically to produce localized recurrent lesions. However, these viruses can also cause severe disease such as recurrent keratitis leading potentially to blindness, as well as encephalitis, and systemic disease in neonates and immunocompromised patients. Although antiviral therapy has allowed continual and substantial improvement in the management of both primary and recurrent infections, resistance to currently available drugs and long-term toxicity pose a current and future threat that should be addressed through the development of new antiviral compounds directed against new targets.
Herpes rọrun (herpes simplex) ní àwọn oríṣi méjì: iru 1 (HSV-1) àti iru 2 (HSV-2). HSV-1 máa ń fa àkóràn ní ayíká ẹnu, nígbà tí HSV-2 máa ń fa àkóràn ní abẹ́ ara. Wọ́n tan kaakiri nípasẹ̀ ìbáṣepọ̀ taara pẹ̀lú ẹni tí ó ní àkóràn. Abe Herpes ni a kà sí àrùn ìbálòpọ̀; ó lè tan sí ọmọ nígbà ìbímọ. Lẹ́yìn ìkólu, ọlọ́jẹ náà ń gbé ara rẹ̀ lọ sí àwọn sẹẹli ara, níbi tí ó ti máa ń gbé pẹ̀lú ìgbésí ayé. Àwọn àǹfààní tó ń fa ìbáyẹ́̀pọ̀̀ lè jẹ́: idinku iṣẹ́ àgbórára, àìlera, àti ìfarahàn sí oorun.
Ní ọ̀pọ̀ ìgbà, a máa ń lo àwọn oògùn antiviral nígbà tí aami aisan bá hàn. Oògùn antiviral tó ń jẹ́ àìmọ̀ọ́kan lè wúlò fún ẹni tí ó ní àkóràn nígbà gbogbo. Kò sí àjẹ́rìà tó wà, ó sì tún jẹ́ pé àjẹ́rìà shingles kò lè dènà Herpes simplex. Ìtọ́jú pẹ̀lú oògùn apakokoro bí aciclovir tàbí valaciclovir lè dín ààmì aisan kù.
Ọ̀pọ̀ àgbáyé ní àkóràn HSV-1 tàbí HSV-2 láàrin 60 % sí 95 % àwọn agbalagba. HSV-1 máa ń ní àkóràn nígbà ìgbà ewe. Àwọn ènìyàn miliọnù 536 ní ayé (16 % ti olùgbé) ti ní àkóràn HSV-2 gẹ́gẹ́ bíi ọdún 2003, pẹ̀lú àkúnya tó pọ̀ jù lọ láàrin àwọn obìnrin àti àwọn orílẹ̀-èdè tó ń ṣìdágbà. Ọ̀pọ̀ ènìyàn tí ó ní HSV-2 kò mọ̀ pé wọ́n ti ní àkóràn.
○ Itọju - Oògùn OTC
Yàgò fún ìfarahàn ara, bíi fífi ọmọ kan lórí, nígbà tí àkúnya wà, nítorí pé ìbáṣepọ̀ lè tan àrùn náà sí àwọn míì. Ó yẹ kí o sinmi, kí o sì máa yá ara rẹ̀ kúrò nínú mímu ọtí.
#Acyclovir cream